您当前的位置:

Epertinib

(Synonyms: S-22611)
目录号: PL01600
Epertinib (S-22611) 是一种口服有效的,可逆的,选择性的 EGFR,HER4 和 HER2 抑制剂,IC50 值分别为 1.48 nM,2.49 nM 和 7.15 nM。Epertinib 具有高效的抗肿瘤活性。
CAS No. :908305-13-5
商品编号 规格 价格 会员价 是否有货 数量
PL01600-1mg 1mg ¥3536.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
*注意事项:下单时请联系销售核实产品价格及货期,避免后续产生不便,感谢支持!
中文名称
Epertinib
中文别名
艾培替尼;化合物 T11213L
英文名称
Epertinib
英文别名
S-22611,Epertinib;Epertinib;Epertinib (S-222611;S222611);(S,Z)-1-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)but-2-yn-1-one O-morpholin-3-ylmethyl oxime;2-Butyn-1-one, 1-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-, O-[(3R)-3-morpholinylmethyl]oxime, (1Z)-;S-22611;(1Z)-1-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-butyn-1-one O-[(3R)-3-morpholinylmethyl]oxime (ACI)
Cas No.
908305-13-5
分子式
C30H27ClFN5O3
分子量
560.02
包装储存
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
详情描述
Epertinib (S-22611) 是一种口服有效的,可逆的,选择性的 EGFR,HER4 和 HER2 抑制剂,IC50 值分别为 1.48 nM,2.49 nM 和 7.15 nM。Epertinib 具有高效的抗肿瘤活性。
产品详情
Epertinib (S-22611) 是一种口服有效的,可逆的,选择性的 EGFR,HER4 和 HER2 抑制剂,IC50 值分别为 1.48 nM,2.49 nM 和 7.15 nM。Epertinib 具有高效的抗肿瘤活性。
生物活性
Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC 50 s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity.
性状
Solid
IC50 & Target[1][2]
EGFR 1.48 ± 0.0 nM (IC50) HER4 2.49 ± 0.1
体外研究(In Vitro)
Epertinib inhibits the phosphorylation of EGFR and HER2 in NCI-N87 cells, with IC50 values of 4.5 and 1.6 nM, respectively.
Epertinib shows inhibitory activity against MDA-MB-361 cell, with an IC50 of 26.5 nM.
Epertinib (0-10 μM, 72 h) can selectively inhibit the proliferation of a range of cancer cell lines expressing EGFR and/or HER2. has not independently confirmed the accuracy of these methods. They are for reference only.t"
体内研究(In Vivo)
Epertinib (0-100 mg/kg, Orally, once daily for 28 days) shows antitumor activity.
Epertinib (50 mg/kg, Orally, once daily for 30 days) significantly reduces the brain tumor volume.
Epertinib (0-50 mg/kg, Orally, once daily for 10-28 days) significantly inhibits the tumor growth in a dose-dependent manner. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
参考文献
[1]. Tanaka Y, et al. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity. Sci Rep. 2018 Jan 10;8(1):343.
[2]. Tanaka H, et al. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Sci. 2014 Aug;105(8):1040-8.
搜索质检报告(COA)
[1]. Tanaka Y, et al. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity. Sci Rep. 2018 Jan 10;8(1):343.
[2]. Tanaka H, et al. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Sci. 2014 Aug;105(8):1040-8.

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2